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Abstract
Introduction: The objective of this guideline is to outline the appropriate use of methylprednisolone sodium succinate (MPSS)
in patients with acute spinal cord injury (SCI).
Methods: A systematic review of the literature was conducted to address key questions related to the use of MPSS in acute SCI. A
multidisciplinary Guideline Development Group used this information, in combination with their clinical expertise, to develop
recommendations for the use of MPSS. Based on GRADE (Grading of Recommendation, Assessment, Development and Evaluation),
a strong recommendation is worded as “we recommend,” whereas a weaker recommendation is indicated by “we suggest.”
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Results: The main conclusions from the systematic review included the following: (1) there were no differences in motor score
change at any time point in patients treated with MPSS compared to those not receiving steroids; (2) when MPSS was admi-
nistered within 8 hours of injury, pooled results at 6- and 12-months indicated modest improvements in mean motor scores in the
MPSS group compared with the control group; and (3) there was no statistical difference between treatment groups in the risk of
complications. Our recommendations were: (1) “We suggest not offering a 24-hour infusion of high-dose MPSS to adult patients
who present after 8 hours with acute SCI”; (2) “We suggest a 24-hour infusion of high-dose MPSS be offered to adult patients
within 8 hours of acute SCI as a treatment option”; and (3) “We suggest not offering a 48-hour infusion of high-dose MPSS to adult
patients with acute SCI.”
Conclusions: These guidelines should be implemented into clinical practice to improve outcomes and reduce morbidity in SCI
patients.
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spinal cord injury, MPSS, methylprednisolone sodium succinate, guideline, acute spinal cord injury
Summary of Recommendations
We suggest not offering a 24-hour infusion of high-dose
MPSS to adult patients who present after 8 hours with
acute spinal cord injury.
Quality of Evidence: Moderate
Strength of Recommendation: Weak
We suggest a 24-hour infusion of high-dose MPSS be
offered to adult patients within 8 hours of acute spinal
cord injury as a treatment option.
Quality of Evidence: Moderate
Strength of Recommendation: Weak
We suggest not offering a 48-hour infusion of high-dose
MPSS to adult patients with acute spinal cord injury.
Quality of Evidence: No included studies
Strength of Recommendation: Weak
Introduction
Within the context of acute spinal cord injury (SCI), preclinical
animal studies have demonstrated mixed results with regard to
the neuroprotective actions of methylprednisolone sodium suc-
cinate (MPSS).1-4 Several randomized controlled trials, includ-
ing the National Acute Spinal Cord Injury Studies (NASCIS),
have investigated the efficacy and safety of MPSS in patients
with acute SCI and comprise the largest therapeutic studies
completed in the history of SCI research.5-8 Although the inter-
pretation of and reaction to the results of these studies have
varied over time, their publication led to the widespread adop-
tion of this therapy by clinicians throughout the world. As
evidence of this, in a 2006 survey study polling the membership
of the North American Spine Society, 86% of respondents
indicated that they would choose to administer MPSS to SCI
patients as per the recommendations of the NASCIS II and III
studies; however, concerns surrounding medicolegal reprisal
for not administrating MPSS was listed as the major factor
motivating decision making in a large faction of these
respondents.9
In spite of the extensive use of MPSS for SCI over the past
several decades, the appropriateness of this treatment remains a
contentious topic.10,11 Opponents of the routine use of MPSS
for acute SCI have highlighted concerns regarding the conduct
of the NASCIS trials and the reported results. These include the
reliance on subgroup analysis (particularly based on timing of
MPSS initiation), the small reported effect size for neurologic
improvement, and the potential for harmful and serious adverse
events.12 In order to resolve the existing controversy, a number
of attempts have been made to review the existing evidence,
with an aim to provide clinicians with specific evidence-based
recommendations related to this treatment.13,14
Two clinical practice guidelines were developed by the
Congress of Neurological Surgeons (CNS) and the American
Association of Neurological Surgeons (AANS).13,15 Despite a
similar evidence base, there were significant differences in the
recommendations proposed in 2002 versus those developed in
2013. Specifically, in 2002, the expert panel recommended the
administration of MPSS for either 24 or 48 hours in patients
with SCI, with the caveat that this treatment should be under-
taken with the knowledge that the evidence suggesting harmful
side effects is more consistent than any suggestion of clinical
benefit.15 In contrast, the 2013 guidelines proposed a level I
recommendation against the use of MPSS based on the follow-
ing reasoning: (1) MPSS is not approved by the Food and Drug
Administration for this application; (2) there is no Class I or
Class II evidence supporting a clinical benefit of MPSS; and (3)
there is Class I, II, and III evidence indicating that high-dose
steroids are associated with harmful side effects including
death.13 These conflicting recommendations, as well as
ongoing debate within the clinical community, has left the
attending physician in a precarious position when faced with
the decision to administer this treatment in the acute care
setting.
This guideline aimed to reexamine existing evidence to clar-
ify the controversy surrounding the use of MPSS in patients
with acute SCI. Furthermore, in order to bridge the gap
between the 2002 and 2013 recommendations, this guideline
distinguished between (1) a 24- versus a 48-hour infusion of
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MPSS and (2) the administration of MPSS within versus after 8
hours of injury. The Guideline Development Group (GDG)
agreed that it was necessary to separate our recommendations
based on these groups given reported differences in the
literature.
The ultimate goal of this guideline is to improve outcomes
and reduce morbidity in patients with SCI by promoting stan-
dardization of care and encouraging clinicians to make more
evidence-informed decisions. As is typical, this guideline is not
intendent to supersede professional judgement or clinical deci-
sion making that considers individual patient circumstances,
interests, and needs. An introductory article in this focus issue
provides further background on SCI and summarizes the ratio-
nale, scope, and specific aspects of care covered by this guide-
line. This article is titled “A Clinical Practice Guideline for the
Management of Acute Spinal Cord Injury: Introduction, Ratio-
nale, and Scope.” These guidelines are intended for use by first
responders, emergency room physicians, critical care special-
ists, neurologists, and spine surgeons. The public should also be
aware of the potential risks and benefits of MPSS in order to
facilitate shared decision making.
Methods
This guideline was developed under the auspices of AOSpine
North America, AOSpine International, and the AANS/CNS.
A multidisciplinary GDG was formed and consisted of clini-
cians from a broad range of specialties as well as patient rep-
resentation. The GDG was solely responsible for guideline
development and was editorially independent from all funding
sources. Members were required to disclose financial and intel-
lectual conflicts of interest (see Appendix, Chapter 2, available
in the online version of the article). A guideline development
protocol, based on the Conference on Guideline Standardiza-
tion checklist,16,17 was created to outline the rationale and
scope of the guideline and to direct its development. Systematic
reviews were conducted based on accepted methodological
standards to summarize the evidence informing our recommen-
dations. Differences between this systematic review and those
previously published include the following: (1) our review was
conducted by external methodologists with no intellectual con-
flicts of interest and (2) studies were only included in this
review if they were randomized controlled trials or observa-
tional studies that controlled for baseline motor status and/or
completeness of injury. As a result, our meta-analysis sum-
marizes the results from the highest quality studies published
to date. For the sake of thoroughness, this review also evaluated
previous systematic reviews using the AMSTAR score in order
to better gauge how other groups, including the AANS/CNS,
assessed the evidence on this topic.
Methods outlined by the Grading of Recommendation,
Assessment, Development and Evaluation (GRADE) Working
Group were used to assess the overall quality (strength) of
evidence for critical outcomes.18,19 The GRADE Guideline
Development Tool was used to document the process, rank the
importance of outcomes, weigh the benefits and harms of
various options, and determine the strength of recommenda-
tions.20-23 Methodologists with no financial or intellectual con-
flicts of interest worked closely with clinical authors to conduct
the systematic reviews and provided methodological expertise
on the guideline development process. Guideline development
methods are provided in another article included in this focus
issue: “Guidelines for the Management of Degenerative Cervi-
cal Myelopathy and Acute Spinal Cord Injury: Development
Process and Methodology.”
Clinical Recommendations
Part 1. The Use of 24-Hour High-Dose
Methylprednisolone Sodium Succinate After 8 Hours
of Spinal Cord Injury
Population Description: Patients with acute SCI
Key Question: Should a 24-hour infusion of high-dose
MPSS be administered to adult patients with acute SCI
after 8 hours after injury?
Recommendation 1: We suggest not offering a 24-hour
infusion of high-dose MPSS to adult patients who
present after 8 hours with acute SCI.
Quality of Evidence: Moderate
Strength of Recommendation: Weak
Evidence Summary
A systematic review of the literature and meta-analysis were
conducted to address the following key questions: In adult
patients with acute complete or incomplete traumatic SCI, (1)
What is the efficacy and effectiveness of MPSS compared with
no pharmacological treatment? (2) What is the safety profile of
MPSS compared with no pharmacological treatment? (3) What
is the evidence that MPSS has differential efficacy or safety in
subpopulations? With respect to study design, all randomized
controlled trials were included as well as observational studies
that controlled for baseline severity of injury. This systematic
review is published elsewhere in this focus issue.
Three randomized controlled trials (4 publications)5,6,24,25
and one prospective cohort study26 evaluated the efficacy of
MPSS compared with no pharmacological treatment. Based on
the results from the trials, there was no effect of MPSS on
motor function at 6 weeks (mean difference ¼ 1.23, 95% con-
fidence interval [CI] ¼ 1.08 to 3.54, P ¼ .30), 6 months
(mean difference ¼ 1.19, 95% CI ¼ 2.34 to 4.72, P ¼ .51),
or 12 months (mean difference ¼ 1.17, 95% CI ¼ 4.80 to
2.47, P ¼ .53). Furthermore, the observational study by Eva-
niew et al reported no difference between patients who did and
did not receive MPSS in terms of total motor recovery at 3
months (mean difference ¼ 0.40, 95% CI ¼ 8.27 to
7.47).26 Pinprick sensation was significantly improved at 6
months in one randomized controlled trial (mean difference
¼ 3.37, 95% CI ¼ 0.75 to 5.99, P ¼ .01)6 but not in 2 other
trials at 12 months (mean difference ¼ 0.18, 95% CI ¼ 2.66
to 3.02, P ¼ .90).6,25 Similar results were observed for light
touch. In summary, there is moderate evidence that MPSS
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administered according to the dose and duration of the NASCIS
protocol confers no benefit compared with no treatment or
placebo in motor recovery, pinprick, or light touch when initi-
ated at indiscriminate time periods following SCI.
In terms of safety, there was no statistically significant dif-
ference between groups in the pooled risk of death (risk differ-
ence ¼ 1.51, 95% CI ¼ 4.13 to 1.12, P ¼ .26), wound
infection (risk difference ¼ 0.98, 95% CI ¼ 1.70 to 3.66, P
¼ .47), gastrointestinal hemorrhage (risk difference ¼ 4.51,
95% CI ¼ 1.92 to 10.94, P ¼ .17), sepsis (risk difference
¼ 0.74, 95% CI ¼ 2.88 to 4.35, P ¼ .69), pulmonary embo-
lism (risk difference ¼ 2.94, 95% CI ¼ 0.15 to 6.03), urinary
tract infection (risk difference¼ 1.73, 95% CI¼5.04 to 8.49,
P ¼ .62) or pneumonia (risk difference ¼ 4.69, 95% CI ¼
3.19 to 12.57, P ¼ .24; moderate level evidence). One pro-
spective nonrandomized study, however, evaluated the risk of
one or more complications and found a lower risk in those
receiving MPSS, after controlling for severity of injury and
other baseline differences (risk difference ¼ 12.59%, 95%
CI ¼ 22.10 to 3.09, P ¼ .009; very low level evidence).27
Rational for Recommendation
The outcomes ranked as critical for decision making were
change in motor and sensory scores and risk of major compli-
cations. The strength of evidence for findings related to these
outcomes was moderate; across studies, there was no serious
risk of bias, no serious inconsistency or indirectness, and unde-
tected publication bias. The majority of the GDG agreed that
the overall certainty of evidence was moderate (low ¼ 2; mod-
erate ¼ 18).
The GDG unanimously agreed that there was probably no
important uncertainty or variability about how much stake-
holders value the main outcomes. Clinicians, patients, and
payers would similarly value improved motor and sensory
scores and reduced risk of major complications.
The anticipated desirable effects were improved motor
scores, pinprick sensation, and light touch. There were no dif-
ferences in motor scores at 6 weeks (P ¼ .30), 3 months (P ¼
.92), 6 months (P ¼ .51), or 12 months (P ¼ .53) in patients
treated with MPSS compared with those not receiving steroids.
Furthermore, there were no differences in pinprick or light
touch at 6 weeks or 12 months between treatment groups. At
6 months, however, patients treated with MPSS had signifi-
cantly better pinprick sensation and light touch than patients
not treated with steroids. The GDG agreed that the desirable
anticipated effects are (probably) not large (no ¼ 11; probably
no ¼ 10; probably yes ¼ 2) since the existing evidence (mod-
erate strength) does not support a treatment of MPSS after 8
hours of injury.
The anticipated undesirable effects of MPSS include com-
plications such as death, wound infection, gastrointestinal
hemorrhage, sepsis, urinary tract infection, pneumonia, and
decubiti. Based on the evidence, there is no statistically signif-
icant difference between treatment groups in the pooled risk of
any of these complications. There was a weak trend for
increased risk of pulmonary embolism in the MPSS group;
however, the clinical impact of this complication on long-
term outcomes is largely unknown. The GDG unanimously
agreed that the undesirable anticipated effects are probably
small. Furthermore, the anticipated desirable effects are prob-
ably not large relative to the undesirable effects given that
MPSS administered after 8 hours of injury does not result in
statistically or clinically significant improvements (no ¼ 4;
probably no ¼ 17).
In the absence of literature, the GDG used their clinical
expertise to discuss the resources required to administer MPSS
to patients with SCI. The GDG unanimously agreed that the
resources required are probably small since MPSS is an off-
patent drug with low associated costs. Unfortunately, there
were no studies evaluating the cost-effectiveness of MPSS in
patients with SCI; as a result, the cost-benefit ratio is uncertain.
The GDG unanimously believed that a recommendation for
MPSS in patients with SCI would reduce health inequities since
this drug is available at most health centers and is inexpensive.
The option of administering MPSS after 8 hours of injury is
probably not acceptable to key stakeholders as it does not result
in long-term neurologic recovery. Finally, the GDG unani-
mously agreed that this option is probably feasible to imple-
ment. There are limited foreseeable barriers from a cost and
process standpoint, although this may be variable across dif-
ferent institutions.
Considering all these factors, the GDG voted that the unde-
sirable consequences probably outweigh the desirable conse-
quences in most settings (n ¼ 16/18); this led to the formation
of a weak recommendation against the use of a 24-hour infu-
sion of high-dose MPSS to adult patients who present after 8
hours of injury (n ¼ 16/21). Although this treatment is feasible
to implement, is unlikely to increase health inequity, and has
not shown statistically or clinically significant evidence of
harm, these factors are mitigated by the lack of demonstrated
efficacy.
Part 2. The Use of 24-Hour High-Dose
Methylprednisolone Sodium Succinate Within 8 Hours
of Spinal Cord Injury
Population Description: Patients with acute SCI
Key Question: Should a 24-hour infusion of high-dose
MPSS be administered to adult patients with acute SCI
within 8 hours of injury?
Recommendation 2: We suggest a 24-hour infusion of
high-dose MPSS be offered to adult patients within 8
hours of acute SCI as a treatment option.
Quality of Evidence: Moderate
Strength of Recommendation: Weak
Evidence Summary
The systematic review also aimed to evaluate whether MPSS
has differential efficacy or safety issues in subpopulations. In
the study by Bracken et al, there was a differential effect of
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MPSS on motor recovery compared with controls depending on
the timing of MPSS administration.5 Patients receiving MPSS
within 8 hours had a mean 4.8- and 5.2-point improvement in
motor scores at 6- and 12-month follow-up compared with a
mean 3.9- and 5.8-point deterioration when administered after
8 hours. There was no evidence of a differential effect of the
timing of MPSS administration on pinprick or light touch.
Two additional randomized controlled trials24,25 and one
prospective observational study26 compared MPSS versus con-
trol in patients receiving treatment within 8 hours. Based on the
randomized controlled trials, pooled results at final follow-up
(6 or 12 months) demonstrated a modest improvement of 3.88
(95% CI ¼ 0.50 to 7.27, P ¼ .02) in mean motor scores in the
MPSS group compared with the control group. When adding
the results of the prospective cohort study, this mean difference
decreased to 3.21 (95% CI ¼ 0.10 to 6.33, P ¼ .04). In sum-
mary, there is moderate evidence suggesting a small benefit in
motor recovery when MPSS is administered within 8 hours of
injury compared with no treatment.
With respect to safety, risk of complications was not sepa-
rately evaluated for patients treated within 8 hours of injury.
Rationale for Recommendation
This question differs from Part 1 as it focuses on the efficacy
and safety of MPSS administered within 8 hours of injury. The
outcomes ranked as most critical for decision making were
change in motor and sensory scores and risk of major compli-
cations. The strength of evidence for findings related to these
outcomes was moderate; across 3 randomized controlled trials
and 1 prospective cohort study, there was no serious risk of
bias, no serious inconsistency or indirectness, and undetected
publication bias. There, however, was a serious risk of impre-
cision, which resulted in a downgrade in the overall quality of
the evidence. The GDG unanimously agreed that the overall
certainty of evidence was moderate.
There was discussion surrounding whether an analysis was
planned a priori to evaluate the effect of timing of MPSS
administration. Using criteria suggested by Oxman and
Guyatt,28 the methodologists confirmed that the subgroup anal-
yses were valid based on GRADE criteria: (1) was the subgroup
variable specified at baseline; (2) was the difference statisti-
cally significant; (3) did the hypothesis precede rather than
follow the analysis; (4) was the subgroup analysis one of a
smaller number of hypotheses tested; (5) was the difference
suggested by comparisons within rather than between studies;
(6) was the difference consistent across studies; and (7) is there
indirect evidence that supports the hypothesized difference? In
the study by Bracken et al, 2 subgroup hypotheses were tested,
one related to the timing of MPSS administration and the other
to the severity of injury.5 The subgroups were specified prior to
randomization as “early” or “late” administration of MPSS
relative to the time of injury; however, the exact cutoff (8
hours) was not selected at baseline, but chosen after data col-
lection based on the median time from injury to treatment.
Subsequent studies used this 8-hour cut point in their analyses,
which allowed for data pooling and meta-analysis.24-26 There
was a statistically significant difference in motor scores
between patients receiving MPSS within 8 hours of injury and
those treated after 8 hours of injury. In addition, the point
estimates were similar in the studies by Bracken et al5 and
Otani et al,24 and the confidence limits of the estimate reported
by Pointillart et al25 nearly overlapped the entire confidence
intervals reported in the other 2 studies. Finally, indirect evi-
dence from a number of preclinical SCI studies have demon-
strated the potential for MPSS, when administered early
postinjury, to improve neurobehavioral outcomes and/or
reduce the extent of neural tissue cavitation by attenuating
membrane lipid peroxidation.1-3
The GDG unanimously agreed that there was probably no
important uncertainty or variability about how much stake-
holders value the main outcomes. Clinicians, patients, and
payers would similarly value improved motor and sensory
scores and reduced risk of major complications.
The anticipated desirable effects were improved motor
scores, pinprick sensation, and light touch. Pooled results at
6- or 12-month follow-up indicate a modest improvement in
mean motor scores in the MPSS group compared with the
control group (Effect size: 3 randomized controlled trials:
3.88, 95% CI ¼ 0.50 to 7.27, P ¼ .02; 3 randomized controlled
trials þ 1 prospective cohort ¼ 3.21, 95% CI ¼ 0.10 to 6.33, P
¼ .04). It is difficult to determine whether these changes rep-
resent clinically important improvements as the minimum
clinically important differences of neurological outcomes have
yet to be established; however, even a small difference can
substantially improve a patient’s quality of life. The GDG were
either uncertain or believed the desirable effects were probably
not large (no ¼ 1; probably no ¼ 8; uncertain ¼ 10; probably
yes ¼ 3).
The anticipated undesirable effects of MPSS include
complications such as death, wound infection, gastrointest-
inal hemorrhage, sepsis, urinary tract infection, pneumonia,
and decubiti. Based on the evidence, there is no statistically
significant difference between treatment groups in the
pooled risk of any of these complications. There was a weak
trend for increased risk of pulmonary embolism in the
MPSS group; however, the clinical impact of this complica-
tion on long-term outcomes is largely unknown. Further-
more, the risk of complications was not separately
evaluated for patients treated within 8 hours of injury. The
GDG unanimously agreed that the undesirable anticipated
effects are probably small. The GDG group were either
uncertain or believed that the desirable effects (motor recov-
ery) are probably large relative to the undesirable effects
(complications/mortality) (probably no ¼ 1; uncertain ¼
11; probably yes ¼ 9; yes ¼ 2). There was substantial
discussion throughout the course of voting; specifically, the
GDG agreed to define a “large effect” as a clinically impor-
tant change. This discussion may partially explain the dis-
crepancy between the voting results for the size of the
anticipated desirable effects and the relative size of antici-
pated desirable to undesirable effects.
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In the absence of literature, the GDG used their clinical
expertise to discuss the resources required to administer MPSS
to patients with SCI. The GDG unanimously agreed that the
resources required are probably small as MPSS is an off-patent
drug with low associated costs. Unfortunately, there were no
studies evaluating the cost-effectiveness of MPSS in patients
with SCI; however, the GDG believed that the incremental cost
is probably small relative to the net motor benefits.
The GDG unanimously believed that a recommendation for
MPSS within 8 hours of injury would reduce health inequities
since this drug is available at most health centers and is inex-
pensive. The option of administering MPSS within 8 hours of
injury is probably acceptable to key stakeholders as there is
potential for small to modest improvements in neurologic
recovery at no increased risk of death or other complications.
Given that even small improvements in motor function can
translate to substantial gains in quality of life, both patients
and clinicians would find this option acceptable. Finally, the
GDG agreed that this option is probably feasible to implement
as there are limited foreseeable barriers from a cost and process
standpoint (probably no ¼ 1; probably yes ¼ 15; yes ¼ 2;
varies ¼ 5). Potential barriers include establishing a diagnosis
of SCI and administering the drug within 8 hours of injury.
Considering all these factors, the GDG voted that the desir-
able consequences probably outweigh the undesirable conse-
quences in most settings (n ¼ 15/21); this led to the formation
of a weak recommendation that a 24-hour infusion of high-dose
MPSS be considered as a treatment option for adult patients
who present within 8 hours of traumatic SCI (n ¼ 17/19).
Although the effect size for motor recovery is small (3-4 motor
points), this change may be important in certain patients where
even small motor improvements may have important func-
tional consequences.
Part 3. The Use of 48-Hour High-Dose
Methylprednisolone Sodium Succinate in Patients
With Spinal Cord Injury
Population Description: Patients with acute SCI
Key Question: Should a 48-hour infusion of high-dose
MPSS be administered to adult patients with acute
SCI?
Recommendation 3: We suggest not offering a 48-hour
infusion of high-dose MPSS to adult patients with
acute SCI.
Quality of Evidence: No included studies
Strength of Recommendation: Weak
Evidence Summary
There were no studies included in the systematic review
(reported elsewhere in this issue) that addressed the efficacy
of a 48-hour high-dose infusion of MPSS relative to placebo or
no treatment. NASCIS III, however, compared a 24-hour ver-
sus 48-hour infusion of high-dose MPSS.8 Based on the results
from this study, there was a significantly higher incidence of
severe pneumonia (P ¼ .02) in the 48-hour group compared
with the 24-hour group. Furthermore, there was an increased
incidence of severe sepsis in the 48-hour group; however, the
difference between the 24-hour and 48-hour groups was within
the limits of chance for this outcome (P ¼ .07). In summary,
there may be an increased incidence of severe pneumonia and
sepsis when the duration of infusion increases from 24 hours to
48 hours.
Rational for Recommendation
The outcomes ranked as most critical for decision making were
change in motor and sensory scores and risk of major compli-
cations. There were no included studies that addressed the
efficacy and safety of a 48-hour high-dose infusion of MPSS
relative to placebo or no treatment. The evidence for this rec-
ommendation was therefore indirect and derived from the
NASCIS III study, which compared the safety of a 24-hour and
48-hour infusion of high-dose MPSS.8
The GDG unanimously agreed that there was probably no
important uncertainty or variability about how much stake-
holders value the main outcomes. Clinicians, patients, and
payers would similarly value improved motor and sensory
scores and reduced risk of major complications.
In the absence of evidence, the GDG unanimously agreed
that it was uncertain whether the anticipated desirable and
undesirable effects of a 48-hour infusion of high-dose MPSS
were large/small. In the NASCIS III study, however, there was
a significantly higher incidence of severe pneumonia and
severe sepsis in the 48-hour cohort compared with the 24-
hour cohort.8
In the absence of literature, the GDG used their clinical
expertise to discuss the resources required to administer MPSS
to patients with SCI. The GDG unanimously agreed that the
resources required are probably small as MPSS is an off-patent
drug with low associated costs. Unfortunately, there were no
studies evaluating the cost-effectiveness of MPSS in patients
with SCI; as a result, the cost-benefit ratio is uncertain.
The GDG unanimously believed that a recommendation for
MPSS in patients with SCI would reduce health inequities since
this drug is available at most health centers and is inexpensive.
The option of administering a 48-hour infusion of high-dose
MPSS is probably not acceptable to key stakeholders as there is
no evidence to support its efficacy. Furthermore, a 48-hour
infusion may be associated with increased infectious complica-
tions. Finally, the GDG unanimously agreed that this option is
probably feasible to implement. There are limited foreseeable
barriers from a cost and process standpoint, although this may
be variable across different institutions.
Considering all these factors, the GDG voted that the unde-
sirable consequences probably outweigh the desirable conse-
quences in most settings (n ¼ 19/24); this led to the formation
of a weak recommendation against the use of a 48-hour infu-
sion of high-dose MPSS to adult patients with SCI (n¼ 15/24).
Although this treatment is feasible to implement and is unlikely
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to increase health inequities, these factors are mitigated by the
lack of demonstrated efficacy and potential for harm.
Further Justification for Changes
in Recommendations
As indicated previously, this guideline aimed to consolidate the
recommendations from the 2002 and 2013 AANS/CNS guide-
lines. The discrepancies between our recommendations and
those proposed in 2002 and 2013 are largely a result of the
group comparisons we made; specifically, we distinguished
between a 24-hour versus 48-hour infusion of MPSS as well
as between administration within and after 8 hours of injury.
Similar to the AANS/CNS guidelines, our systematic review
indicated that, across all patients, MPSS does not confer any
clinical benefit compared with no pharmacological treatment.13
In patients treated within 8 hours of injury, however, our meta-
analysis supported a near 4-point difference in motor scores
between groups (favoring MPSS). In terms of safety, our sys-
tematic review only indicated a significant difference in risk of
complications between patients treated with a 24-hour versus a
48-hour infusion. In contrast, there were no observed differ-
ences in harmful side effects between a 24-hour MPSS group
and a control group. In fact, a study by Wilson et al indicated
that treatment with MPSS was associated with a reduced risk of
experiencing one or more complications; this finding, however,
was based on very low level evidence.
The systematic review by Hurlbert reported a higher inci-
dence of gastrointestinal hemorrhage, wound infection, and
pulmonary embolism in patients treated with MPSS compared
with controls.13 Although none of these findings were reported
as statistically significant, the authors acknowledged that none
of these comparisons were properly powered to avoid Type II
error. A number of studies were excluded in our systematic
review that were included in the one published by Hurlbert;
differences in inclusion criteria may partly explain the discre-
pancies in results between these 2 reviews and, consequently,
differences in recommendations. Our review targeted either
randomized controlled trials or observational studies that con-
trolled for baseline severity score. We are confident that the
studies synthesized in our meta-analysis truly reflect the high-
est quality of evidence published on this topic. Although some
of the comparisons were not properly powered to detect a dif-
ference between treatment groups, this limitation was reflected
by downgrading the overall strength of evidence for
imprecision.
Evidence Gaps and Future Research
Recommendations
Given that MPSS has the longest track record for use, and has
been the subject of the greatest study and controversy in the
context of SCI, we included an evaluation of this drug in these
guidelines. That said, we acknowledge that there are a number
of new putative neuroprotective agents in the translational
pipeline that have shown promise in preclinical and early phase
clinical studies. At present, however, there is inadequate evi-
dence to justify any recommendation with respect to these
emerging treatments. Future studies evaluating the efficacy
of these agents alone, and in combination with MPSS, would
be of interest. Given the fact that several large, high-quality
randomized controlled trials evaluating MPSS in SCI have
been completed, it would be difficult to justify the initiation
of another similar study, especially in the face of limited
resources and the aforementioned therapies that have yet to
be formally tested in large clinical studies.
Implementation Considerations
It is expected that this guideline will influence clinical practice
and facilitate evidence-based decision making. Dissemination
of the knowledge from this guideline is of critical importance
and will be accomplished at multiple levels:
 Presentation at international spine surgery, critical care,
neurology, anesthesiology, and vascular medicine
conferences
 Scientific and educational courses in symposium format
 Webinar dissemination of information to a broad audi-
ence in an interactive format
 Publication of a focus issue in a peer-reviewed journal
 Submission to the National Guideline Clearinghouse
 AOSpine International Spinal Cord Injury Knowledge
Forum
Potential barriers to implementation include the following:
1. Clinical uptake by surgeons: The use of MPSS in the
setting of traumatic SCI is one of the most contentious
issues in the field. Many clinicians are opposed to the
routine use of MPSS, even within 8 hours of injury, due
to perceived increased risks of complications and mor-
tality. As a result, the decision to administer MPSS in
the acute phase of SCI may remain in the hands of
individual surgeons.
2. Given that SCI occurs in geographically isolated
regions, successful administration of MPSS within 8
hours of injury may be dependent on location of injury
(ie, where the injury occurred) and the local transport
and prehospital systems in place. Furthermore, timely
treatment with MPSS may require administration at the
site of injury or en route to a trauma center by first
responders, which may pose additional logistical
challenges.
Internal Appraisal and External Review
of This Guideline
Vice-chairs of the GDG conducted an internal appraisal of the
final guideline using Appraisal of Guidelines for Research &
Evaluation II (AGREE II) standards.29 A multidisciplinary
group of stakeholders, including patients, were invited to
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externally review the final draft prior to publication. Additional
details of these processes and a summary of conflicts of interest
for external reviewers are found in the accompanying methods
paper.
Plans for Updating
The guidelines will be reviewed by the primary sponsor and the
Vice-Chairs at 3 years to a maximum of 5 years following
publication. The guideline will be updated when new evidence
suggests the need to modify our recommendations. An earlier
update will be considered if there are changes in (1) the evi-
dence related to harms and benefits; (2) outcomes that would be
considered important for decision making; (3) ranking of cur-
rent critical and important outcomes; and (4) available inter-
ventions and resources.30
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